A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration

NCTID	NCT06765980 (View at clinicaltrials.gov)
Description	The goal of this study is to evaluate how safe and tolerable KRIYA-825 (VV-14295) is and to determine how effective it is in reducing the growth of geographic atrophy (GA) lesions in the treated eye in patients with GA secondary to age-related macular degeneration (AMD). (Show More)
Development Status	Active
Indication	Geographic Atrophy Secondary to Age-related Macular Degeneration
Disease Ontology Term	DOID:10871
Compound Name	KRIYA-825
Compound Alias	VV-14295
Sponsor	Kriya Therapeutics, Inc.
Funder Type	Industry
Recruitment Status	Recruiting (Click here for study contact information)
Enrollment Count	62 (ESTIMATED)
Results Posted	Not Available

Target Gene/Variant	CR2-CR1
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	Genetic delivery of therapeutic protein
Route of Administration	Suprachoroidal
Drug Product Type	Viral vector
Target Tissue/Cell
Delivery System	Viral transduction
Vector Type	AAV2
Editor Type
Dose 1	Undisclosed
Dose 2
Dose 3
Dose 4
Dose 5

No.of Trial Sites	2
Locations	New Zealand,Canada